« The Increasing Use Of Antidepressants: Some Reasons For Concern | Main | Mechanism In Memory Development Discovered In Flies That May Help Parkinson’s Patients »
Corcept Therapeutics Announces Commencement Of Next Phase 3 Study With CORLUX(R) For The Treatment Of Psychotic Depression
By Depressed Jane | March 24, 2008
Corcept Therapeutics (NASDAQ: CORT) announced the commencement of its fourth Phase 3 trial, Study 14, evaluating CORLUX for the treatment of the psychotic features of psychotic depression. This trial is a randomized, double-blinded, placebo-controlled study which will enroll up to 450 patients at approximately 25 sites in the United States. In connection with this study Corcept also announced the signing of an agreement with MedAvante, Inc.
Topics: A Depressed Life |